Characterizing the Impact of Hydroxypropylmethyl Cellulose on the Growth and Nucleation Kinetics of Felodipine from Supersaturated Solutions

被引:129
作者
Alonzo, David E. [1 ,2 ]
Raina, Shweta [1 ]
Zhou, Deliang [3 ]
Gao, Yi [2 ]
Zhang, Geoff G. Z. [2 ]
Taylor, Lynne S. [1 ]
机构
[1] Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, W Lafayette, IN 47907 USA
[2] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Global Pharmaceut Operat, N Chicago, IL 60064 USA
关键词
AMORPHOUS SOLID DISPERSIONS; CRYSTAL-GROWTH; AQUEOUS-SOLUTION; INDUCTION TIME; PARTICLE-SIZE; DRUG; CRYSTALLIZATION; PRECIPITATION; IMPURITIES; SOLUBILITY;
D O I
10.1021/cg201590J
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The use of amorphous drugs to generate supersaturated solutions that have the potential to enhance oral drug delivery is currently an area of intense interest. From an in vivo performance standpoint, inhibiting crystallization from these supersaturated systems is extremely important. In this study the ability of a polymer, hydroxypropylmethyl cellulose (HPMC), to inhibit nucleation and crystal growth of felodipine from supersaturated solutions was investigated. Nucleation and bulk crystal growth rates, in the absence and presence of seed crystals, were estimated from de-supersaturation curves. It was found that the presence of ppm levels of predissolved HPMC could inhibit both nucleation and growth of felodipine crystals. Empirical and mechanistic models were used to quantify the magnitude of inhibition. Crystal growth shifted toward an integration-controlled mechanism in the presence of HPMC where the overall impact on the growth rate was found to be strongly dependent on the extent of supersaturation. As predicted by theory, the polymer became less effective as a growth inhibitor with increases in supersaturation. The nucleation rate at similar supersaturations was significantly reduced comparison of the impact of HPMC on nucleation and growth demonstrated that delaying the stabilization of a supersaturated solution than hindering crystal growth. in the presence of HPMC. A direct nucleation was much more crucial to
引用
收藏
页码:1538 / 1547
页数:10
相关论文
共 39 条
[1]   Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution [J].
Alonzo, David E. ;
Zhang, Geoff G. Z. ;
Zhou, Deliang ;
Gao, Yi ;
Taylor, Lynne S. .
PHARMACEUTICAL RESEARCH, 2010, 27 (04) :608-618
[2]   Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug:: In vitro and in vivo evaluations [J].
Ambike, AA ;
Mahadik, KR ;
Paradkar, A .
PHARMACEUTICAL RESEARCH, 2005, 22 (06) :990-998
[3]   An interfacial energy mechanism for the complete inhibition of crystal growth by inhibitor adsorption [J].
Anklam, MR ;
Firoozabadi, A .
JOURNAL OF CHEMICAL PHYSICS, 2005, 123 (14)
[4]   THE KINETICS OF CRYSTAL-GROWTH IN THE PRESENCE OF TAILOR-MADE ADDITIVES [J].
BLACK, SN ;
DAVEY, RJ ;
HALCROW, M .
JOURNAL OF CRYSTAL GROWTH, 1986, 79 (1-3) :765-774
[5]   Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? [J].
Brouwers, Joachim ;
Brewster, Marcus E. ;
Augustijns, Patrick .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2549-2572
[6]  
Byrn S.R., 1999, Solid State Chemistry of Drugs, VSecond
[7]  
Cabrera N., 1958, Growth and Perfection of Crystals. Proceedings of an International Conference on Crystal Growth, P393
[8]  
Erdemir D, 2007, CURR OPIN DRUG DISC, V10, P746
[9]   Crystal habit modifications of ibuprofen and their physicomechanical characteristics [J].
Garekani, HA ;
Sadeghi, F ;
Badiee, A ;
Mostafa, SA ;
Rajabi-Siahboomi, AR .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (08) :803-809
[10]  
Garside J., 2002, Measurement of Crystal Growth and Nucleation Rates, VSecond